• Kymera presented Phase 1 results for KT-621, an oral STAT6 degrader, in healthy Japanese adults at the Japanese Dermatological Association meeting.
• The study supported consistent drug behavior and a favorable tolerability profile versus earlier KT-621 Phase 1 work in non-Japanese volunteers.
• Results cleared the regulatory step needed to enroll patients in Japan into ongoing global Phase 2b trials in atopic dermatitis and asthma.
• Phase 2b readouts are expected by mid-2027 for atopic dermatitis, late 2027 for asthma.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kymera Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606120700PRIMZONEFULLFEED9745901) on June 12, 2026, and is solely responsible for the information contained therein.